Skip to content
Search

Latest Stories

'Prescribers must follow robust monitoring of patients taking hazardous medicines'

The Pharmacists Defence Association (PDA) has urged community pharmacists to remain cautious while prescribing potentially hazardous medicines to the patients with serious ailments.

It's call follows a recent Coroner’s Regulation 28 report which highlighted the death of a patient with chronic liver disease.


According to the Coroner’s report, the patient was attributed to the accumulation of methadone provided by a prescriber which she was unable to eliminate effectively due to impaired liver function.

The case involved a patient with a history of chronic liver disease and opiate dependence. The patient had received repeat prescriptions for codeine phosphate to treat abdominal pain secondary to liver problems.

The patient self-referred to 'Turning Point' for support with opiate dependency in January 2020. Despite noting the existence of chronic liver disease in the patient’s notes and contacting the patient’s GP to ask whether there were any recent blood test results, the prescriber went on to initiate methadone treatment in the absence of a response from the GP and without requesting LFTs themselves.

The patient was commenced on 30ml daily of methadone increasing to 60ml daily over several days. The patient was found dead in February 2020.

The PDA has advised prescribers to check for conditions which might affect drug handling before they prescribe an unfamiliar patient.

The association also suggested pharmacists take potentially impaired drug handling into account when prescribing and familiarise themselves with key drugs where caution is required

“Make sure patients with impaired renal or liver function, or those on high-risk medicines which can cause impairment, have regular blood tests and that those tests are interpreted and acted upon where necessary. Many of the required tests can be found in the PINCER suite of searches and form part of measures in primary care to improve medicines safety,” the PDA said.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less